Preclinical work, especially GLP studies, are costly and critical to the product’s successful regulatory submission. Efficiency and quality in preclinical work begins with a robust preclinical study protocol. Preclinical protocols are the foundation on which reports required by regulatory bodies are built.
What elements in a preclinical study protocol give the study the best opportunity for clarity in a final report that will ultimately be reviewed by regulators? Join GCMI’s Irena Brants and Deepal Panchal for this 30 minute webinar on Thursday, May 14 at 11:00 a.m. EDST to find out.